Advancing our understanding of the brain's complex circuitry
The physical and biological complexity of the human brain has posed a significant challenge in the success of neuroscience research and development. As critical as it is to develop solutions that reach the clinic, it also imperative that we enhance our basic understanding of the human brain in health and disease so that we can develop tools and approaches that increase our efficiency and chances of successful discovery and therapies.
Defining the future of neuroscience discovery
We seek to develop approaches that can enable and enhance our understanding of the brain, the nervous system and brain disease mechanisms, in an organized, systematic and effective way.
To that end, part of our research efforts and collaborations are focused on achieving large scale, high-content brain circuit mapping of both basic and clinical relevance. Benefiting from major advances in chemistry and genetics, we seek to help advance new methods for brain mapping and contribute to the world’s ability to see the brain in full molecular and cellular detail.
This should have implications for all areas of basic and applied neuroscience, and should directly inform potential new therapies, whether drug- based, gene therapy- based or device- based. Hence, we also pursue the development of highly specific gene or cell therapies for specific indications such as dementia, stroke and spinal cord injury.
Key neurobiology areas of development at the Wyss Center:
- Brain mapping: tissue processing / histology, genetic engineering, hardware, human tissue slice culture, organoids, computational analysis and image processing.
- Molecular biology and microscopy
- Cell and gene therapy: collaborating with external research groups and facilities on the development and optimization of pre-clinical and clinical protocols and trials
- Data collection and management
- Obtaining and banking human tissue samples
Our existing facilities and expertise in microscopy, histology and cell culture, and molecular biology will contribute to our expansion into the field of neurobiology.
GliaPharm SA and the Wyss Center enter collaboration to develop new therapies for Alzheimer’s disease
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkersCollaboration
Alzheimer's disease: an alternative hypothesis based on synaptic alterations
New research suggests that targeting proteins essential to neurotransmission could be a promising alternative to treat Alzheimer's diseaseCollaboration
Wyss Center announces the appointment of Dr Richie Kohman as Chief Scientific Officer
Dr Kohman brings more than 15 years of research and industry experience in the development of transformative technologies for healthcare and society.Wyss Center